Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Human Psychopharmacology is Scopus-indexed (Q2, CiteScore 4.5), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by John Wiley and Sons Ltd.
Checked against the index lists dated .
ISSN 0885-6222Verify ISSN ↗1099-1077Verify ISSN ↗
Publisher: John Wiley and Sons Ltd
Cost to publish: About US$4,030 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Psychiatry and Mental Health | 208 / 580 | 64th | Q2 |
| Neurology (clinical) | 157 / 403 | 61st | Q2 |
| Pharmacology (medical) | 118 / 278 | 57th | Q2 |
| Neurology | 89 / 201 | 55th | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1986–present, best quartile Q2, CiteScore 4.5.
Human Psychopharmacology is Q2 in Psychiatry and Mental Health (rank 208 of 580), Q2 in Neurology (clinical) (rank 157 of 403) and Q2 in Pharmacology (medical) (rank 118 of 278), by CiteScore 2025. It is ranked in 4 subject areas in all.
Human Psychopharmacology is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.5, which places it in quartile Q2 at the 64th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.662, quartile Q2, with an H-index of 89.
The publisher lists an article processing charge of about US$4,030 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Human Psychopharmacology is published by John Wiley and Sons Ltd. Its print ISSN is 0885-6222 and its online ISSN is 1099-1077.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Human Psychopharmacology has an h-index of 102 and a 2-year mean of 1.09 citations per paper (OpenAlex). Its Scopus CiteScore is 4.5, quartile Q2. On 2-year citations it ranks #357 of 570 Scopus journals in Psychiatry and Mental Health.
Human Psychopharmacology published 37 papers in 2025; its busiest recent year was 2017 with 85. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2023–2026), authors are most often from United Kingdom (17%), United States (13.4%) and Italy (8.5%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (0.6 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.